Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease.

Xiaoning Chen George Boon-Bee Goh Jiaofeng Huang Yinlian Wu Mingfang Wang Rahul Kumar Su Lin Yue-Yong Zhu

Published in: Journal of clinical and translational hepatology (2022)

NFS is better for predicting advanced fibrosis in MAFLD. FIB-4 can be an alternative choice for MAFLD with high liver enzymes when NFS is unavailable. Novel efficient noninvasive fibrosis scoring systems are highly required for patients with MAFLD.

Keyphrases

liver fibrosis
decision making